The Role of GluN2A and GluN2B Subunits on the Effects of NMDA Receptor Antagonists in Modeling Schizophrenia and Treating Refractory Depression

Neuropsychopharmacology

Volumn 39, Issue 11, 2014, Pages 2673-2680

  Jiménez Sánchez, Laura ^a,b,c   Campa, Leticia ^a,b,c   Auberson, Yves P ^d   Adell, Albert ^a,b,c  

^a INST D INVESTIGACIONS B   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 5-(ALPHA-METHYL-4-BROMOBENZYLAMINO)PHOSPHONOMETHYL-1,4-DIHYDROQUINOXALINE-2,3-DIONE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; DIZOCILPINE MALEATE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NR2B NMDA RECEPTOR; PHENOL DERIVATIVE; PIPERIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; SEROTONIN;

ANIMAL; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; SCHIZOPHRENIA; STEREOTYPY; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; MALE; PHENOLS; PIPERIDINES; PREFRONTAL CORTEX; QUINOXALINES; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SEROTONIN; STEREOTYPED BEHAVIOR;

EID: 84930922363     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.123     Document Type: Article

References (50)

1. Adell A, Jimé nez-Sánchez L, López-Gil X, Romón T (2012). Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophrenia Bull 38: 9-14.
2. Akinfiresoye L, Tizabi Y (2013). Antidepressant effects of AMPA and ketamine combination: Role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 230: 291-298.
3. Amargós-Bosch M, Ló pez-Gil X, Artigas F, Adell A (2006). Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol 9: 565-573.
4. Aragam N, Wang KS, Anderson JL, Liu X (2013). TMPRSS9 and GRIN2B are associated with neuroticism: A genome-wide association study in a European sample. J Mol Neurosci 50: 250-256.
5. Aubers on YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M (2002). 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor compositi on. Bioorg Med Chem Lett 12: 1099-1102.
6. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000). Antidepressant effects of ketamine in depressed patients. Biol Psy chiatry 47: 351-354.
7. Boyce-Rustay JM, Holmes A (2006). Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressantlike effects in mice. Neuropsychopharmacology 31: 2405-2414.
8. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK et al (2013). GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-l ike side effects. Neuropsychopharmacology 38: 729-742.
9. Chaperon F, Mü ller W, Auberson YP, Tricklebank MD, Neijt HC (2003). Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: Preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol 14: 477-487.
10. Chen H-S V Lipton SA 2005 Pharmacological implications of tw o distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. J Pharmacol Exp Ther 314 961-971.
11. Duman RS, Aghajanian GK (2012). Synaptic dysfunction in depression: Potential therapeutic targets. Science 338: 68-72.
12. Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC et al (2013). Altered expression of synapse and glutamate related genes in post-mortem hippoc ampus of depressed subjects. Int J Neuropsychopharmacol 16: 69-82.
13. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009). Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33: 70-75.
14. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E et al (1997). Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283: 1285-1292.
15. Flores-Barrera E, Thomases DR, Heng LJ, Cass DK, Caballero A, Tseng KY (2014). Late adolescent expression of GluN2B transmission in the prefrontal cortex is input-specific and requires postsynaptic protein kinase A and D1 d opamine receptor signaling. Biol Psychiatry 75: 508-516.
16. Gielen M, Siegler Retchless B, Mony L, Johnson JW, Paoletti P (2009). Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459: 703-707.
17. Gilmartin MR, Kwapis JL, Helmstetter FJ (2013). NR2A-and NR2B-containing NMDA receptors in the prelimbic medial prefrontal cortex differentially mediate trace, delay, and contextual f ear conditioning. Learn Mem 20: 290-294.
18. Hanson JE, Weber M, Meilandt WJ, Wu T, Luu T, Deng L et al (2013). GluN2B antagonism affects interneurons and leads to immediate and persistent changes i n synaptic plasticity, oscillations, and behavior. Neuropsychopharmacology 38: 1221-1233.
19. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B (2004). Functional interaction between NMDA and mG lu5 receptors: Effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29: 1259-1269.
20. Hu M, Sun YJ, Zhou QG, Auberson YP, Chen L, Hu Y et al ( 2009). Reduced spatial learning in mice treated with NVP-AAM077 through down-regulating neurogenesis. Eur J Pharmacol 622: 37-44.
21. Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ et al (2012). A randomized, placebocontrolled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 32: 551-557.
22. Jackson ME, Homayoun H, Moghaddam B (2004). NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 101: 8467-8472.
23. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
24. Jentsch JD, Tran A, Taylor JR, Roth RH (1998). Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: Behavioral and neurochemical evidence. Psychopharmacology (Berl) 138: 89-95.
25. Kocsis B (2012). Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 71: 987-995.
26. Koike H, Iijima M, Chaki S (2011). Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224: 107-111.
27. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al ( 1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
28. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
29. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H et al (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754-761.
30. Lipska BK, Weinberger DR (2003). Animal models of schizophrenia. In: Hirsch SRWeinberger DR (eds) Schizophrenia. Blackwell Science: Malden, pp 388-402.
31. Lisman JE Coyle JT Green RW Javitt DC Benes FM Heckers S et al 2008 Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia Trends Neurosci 31 234-242.
32. Lópe z-Gil X, Babot Z, Amargós-Bosch M, Sun? ol C, Artigas F, Adell A (2007). Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32: 2087-2097.
33. Ló pez-Gil X, Jiménez-Sánchez L, Romón T, Campa L, Artigas F, Adell A (2012). Importance of inter-hemispheric prefrontal connection in the effects of non-competitive NMDA receptor antagonists. Int J Neuropsychopharmacol 15: 945-956.
34. Lucki I (1998). The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44: 151-162.
35. Mabrou k OS, Mela F, Calcagno M, Budri M, Viaro R, Dekundy A et al (2013). GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. ACS Chem Neurosci 4: 808-816.
36. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G et al (2008). Cellular mechanisms underlying the antidepressant effects of ketam ine: Role of a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352.
37. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by k etamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
38. Neyton J, Paoletti P (2006). Relating NMDA receptor function to receptor subunit composition: Limitations of the pharmacological approach. J Neurosci 36: 1331-1333.
39. Paxinos G, Watson C (2005). The Rat Brain in Stereotaxic Coordinates. Elsevier/Aca demic Press: Amsterdam.
40. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101, 606, in patients with treatmentrefractory major depressive disorder. J Clin Psychopharmacol 28: 631-637.
41. Sams-Dodd F (1997). Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8: 196-215.
42. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ et al (2014). Lanicemine: A low-trapping NMDA channel bl ocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry, doi:10.1038/mp.2013.130 (e-pub ahead of print).
43. Skolnick P, Popik P, Trullas R (2009). Glutamate-based antidepressants: 20 years o n. Trends Pharmacol Sci 30: 563-569.
44. S mith JW, Gastambide F, Gilmour G, Dix S, Foss J, Lloyd K et al (2011). A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psy chopharmacology (Berl) 205: 203-216.
45. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK et al (2010). Glutamate receptor ion channels: Structure, regulation, and function. Pharm acol Rev 62: 405-496.
46. Wang M, Yang Y, Wang CJ, Gamo NJ, Jin LE, Mazer JA et al (2013). NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron 77: 736-749.
47. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006a ). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
48. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA et al (2006b ). A double-blind, placebocontrolled study of memantine in the treatment of major depression. Am J Psychiatry 163: 153-155.
49. Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I et al (2013). A randomized trial of a low-trapping nonselecti ve N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74: 257-264.
50. Zhang C, Li Z, Wu Z, Chen J, Wang Z, Peng D et al (2014). A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology (Berl) 231: 685-693.